Brexpiprazole in Combination With Sertraline and as Monotherapy in Posttraumatic Stress Disorder
The Journal of Clinical Psychiatry · 2025
DOI: 10.4088/jcp.24m15577 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Psychiatry, 2025. Verfasst von Mary Hobart und 3 weiteren Autor:innen. Beteiligte Einrichtung: Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, New Jersey. Hauptthemen laut MEDLINE: Sertraline, Thiophenes, Stress Disorders, Post-Traumatic, Quinolones. Die Arbeit wurde bisher 4-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, New Jersey.
- Corresponding Author: Mary Hobart, PhD, 508 Carnegie Center Drive, Princeton, NJ 08540 (Mary.Hobart@otsuka-us.com).
- H. Lundbeck A/S, Valby, Denmark.
- Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, Alabama.
Zitieren
APA
Hobart, M., Chang, D., Hefting, N., & Davis, L. L. (2025). Brexpiprazole in Combination With Sertraline and as Monotherapy in Posttraumatic Stress Disorder. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.24m15577
Vancouver
Hobart M, Chang D, Hefting N, Davis LL. Brexpiprazole in Combination With Sertraline and as Monotherapy in Posttraumatic Stress Disorder. The Journal of Clinical Psychiatry. 2025. doi:10.4088/jcp.24m15577
BibTeX
@article{Hobart2025,
author = {Hobart, Mary and Chang, Denise and Hefting, Nanco and Davis, Lori L},
title = {Brexpiprazole in Combination With Sertraline and as Monotherapy in Posttraumatic Stress Disorder},
journal = {The Journal of Clinical Psychiatry},
year = {2025},
doi = {10.4088/jcp.24m15577}
}
EUVIMED